Helsinn ANAM-17-21:Non-Small Cell Lung Cancer and weight loss

What is the Purpose of this Study?

We are doing this study to learn more about how Anamorelin HCl works to prevent weight loss and anorexia in patients with advanced NSCLC.
What is the Condition Being Studied?
Non-Small Cell Lung Cancer

Who Can Participate in this Study?

Adults who:

-Have advanced NSCLC

-Are experiencing weight loss and/or appetite problems

Age Group
Adults
Participating Institutions

What is Involved?

If you choose to join this study, you will:

-Be in this study for up to 27 weeks

-Be randomized (like the flip of a coin) to get the study drug (Anamorelin HC1) or a placebo (harmless medicine)

-Give blood samples

-Complete regular care and visits

Study Details

Full Title
ANAM-17-21 A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of anamorelin HCl for the treatment of malignancy associated weight loss and anorexia in adult patients with advanced non-small cell lung cancer (NSCLC)
Principal Investigator

Contacts
Protocol Number
IRB:
PRO00101263

NCT:
NCT03743064
ClinicalTrials.gov
View on ClinicalTrials.gov